脂质轨迹改善了阿尔茨海默病和轻度认知障碍的风险模型
Bruce A Chase1, Roberta Frigerio2, Chad J Yucus3
1Information Technology, Endeavor Health, Skokie, IL, USA; Pritzker School of Medicine, Chicago, USA.
Journal of lipid research
|November 25, 2024
概括
血脂水平及其在十年中的变化可以预测阿尔茨海默病 (AD) 和轻度认知障碍 (MCI) 风险. 分析胆固醇和甘油三模式可以改善认知衰退风险模型.
科学领域:
- 神经学 神经学
- 心血管科学 心血管科学
- 生物统计学 生物统计学
背景情况:
- 阿尔茨海默病 (AD) 和轻度认知障碍 (MCI) 是严重的公共卫生问题.
- 预测认知能力下降风险仍然是一个挑战,需要新的生物标志物.
- 血脂特征越来越多地被认为对神经退行性疾病的作用.
研究的目的:
- 调查血脂度及其在症状出现前十年的变化是否预测阿尔茨海默病 (AD) 和稳定轻度认知障碍 (MCI) 风险.
- 评估超越遗传因素和当前脂质水平的脂质轨迹和风险预测模型变化的附加值.
主要方法:
- 追溯性,病例控制研究设计,将AD/MCI病例与对照进行比较.
- 参与者按纵向血脂轨迹和胆固醇和甘油三的独立于平均值 (VIM) 的可变性进行分组.
- 风险模型包括脂质数据,APOE基因型,多基因风险得分 (PRS) 和其他混因素.
主要成果:
- 较低的HDL-C轨迹与MCI和AD风险增加有关.
- 非高密度胆固醇-C (MCI) 和总胆固醇 (AD) 的最低VIM五分位数与更高的风险有关.
- 纳入脂质轨迹和VIM改善了风险预测模型,独立于遗传风险得分.
结论:
- 纵向血脂度及其变异性是认知能力下降的重要预测因素.
- 这些脂质标志物为改善AD和MCI风险评估提供了宝贵的见解.
- 了解脂质动态为神经退行性疾病的发病提供了一个新的视角.
关键词:
在这里,APOEOE是APOE.阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.在HDL-C中使用.这就是为什么LDL,LDL是LDL.胆固醇 胆固醇 胆固醇 是一种基于组的轨迹分析.脂质 脂质 脂质 是一种多基因风险评分多基因风险评分.三甲酸甘油三甲酸甘油三甲酸甘油独立于平均值的可变性.更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.8K
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
9.3K
相关概念视频
Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Dementia
96
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
96
